From NAFLD to MAFLD: when pathophysiology succeeds (original) (raw)

LIVER

Nature Reviews Gastroenterology & Hepatology volume 17, pages 387–388 (2020)Cite this article

Subjects

Two new position papers convincingly propose that nonalcoholic fatty liver disease needs a new name — metabolic associated fatty liver disease (MAFLD). A new name for this disease affecting nearly one billion people globally is overdue, as knowledge gained from the past decades has assuringly demonstrated that MAFLD is a purely metabolic disorder.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

$32.99 / 30 days

cancel any time

Subscribe to this journal

Receive 12 print issues and online access

$189.00 per year

only $15.75 per issue

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Fig. 1: MAFLD: an ‘old’ new disease.

References

  1. Ludwig, J., Viggiano, T. R., McGill, D. B. & Oh, B. J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 55, 434–438 (1980).
    CAS PubMed Google Scholar
  2. Fleming, K. A. et al. Mallory bodies in alcoholic and non-alcoholic liver disease contain a common antigenic determinant. Gut 22, 341–344 (1981).
    Article CAS Google Scholar
  3. Beringer, A. & Thaler, H. Relationships between diabetes mellitus and fatty liver [German]. Dtsch. Med. Wochenschr. 95, 836–838 (1970).
    Article CAS Google Scholar
  4. Day, C. P. & James, O. F. Steatohepatitis: a tale of two “hits”? Gastroenterology 114, 842–845 (1998).
    Article CAS Google Scholar
  5. Marchesini, G. et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med. 107, 450–455 (1999).
    Article CAS Google Scholar
  6. Marchesini, G. et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50, 1844–1850 (2001).
    Article CAS Google Scholar
  7. Eslam, M. et al. A new definition for metabolic associated fatty liver disease: an international expert consensus statement. J. Hepatol. https://doi.org/10.1016/j.jhep.2020.03.039 (2020).
    Article PubMed Google Scholar
  8. Eslam, M., Sanyal, A. J. & George, J. International Consensus Panel MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology https://doi.org/10.1053/j.gastro.2019.11.312 (2020).
    Article PubMed Google Scholar
  9. Tilg, H., Zmora, N., Adolph, T. E. & Elinav, E. The intestinal microbiota fuelling metabolic inflammation. Nat. Rev. Immunol. 20, 40–54 (2020).
    Article CAS Google Scholar
  10. Angulo, P. et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver dmetaisease. Gastroenterology 149, 389–397 (2015).
    Article Google Scholar

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University Innsbruck, Innsbruck, Austria
    Herbert Tilg & Maria Effenberger

Authors

  1. Herbert Tilg
  2. Maria Effenberger

Corresponding author

Correspondence toHerbert Tilg.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

About this article

Cite this article

Tilg, H., Effenberger, M. From NAFLD to MAFLD: when pathophysiology succeeds.Nat Rev Gastroenterol Hepatol 17, 387–388 (2020). https://doi.org/10.1038/s41575-020-0316-6

Download citation

This article is cited by